Structure via PubChem · Public domain (PubChem)
cariprazine
Sign in to saveAlso known as RGH 188, RGH-188, Vraylar®, trans-N-{4-[2-[4-(2,3-dichlorophenyl)piperazine-1-yl]ethyl]cyclohexyl}-N’,N’-dimethylurea hydrochloride, Kariprazin
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. It is a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatig
In the Vinony graph
Within Vinony's link graph, cariprazine is referenced by 1,678 other articles, and connects out to fluphenazine, zuclopenthixol and flupentixol.
It is catalogued under topics including 2,3-Dichlorophenylpiperazines, Atypical antipsychotics and Chemicals using indexlabels.
Its subject is documented across 24 Wikipedia language editions.
Key facts
- Drug.image
- Cariprazine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 250
- Drug.image2
- Cariprazine ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 250
- Drug.tradename
- Vraylar, Reagila, Symvenu
- Drug.DailyMedID
- Cariprazine
- Drug.licence_US
- Cariprazine
- Drug.pregnancy_AU
- D
- Drug.routes_of_administration
- By mouth
- Drug.class
- Atypical antipsychotic
- Drug.ATC_prefix
- N05
- Drug.ATC_suffix
- AX15
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_UK
- POM
- Drug.legal_US
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C21H32Cl2N4O
- Molecular weight
- 427.4 g/mol
- IUPAC name
- 3-[4-[2-[4-(2,3-dichlorophenyl)piperazin-1-yl]ethyl]cyclohexyl]-1,1-dimethylurea
- SMILES
- CN(C)C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl
- InChIKey
- KPWSJANDNDDRMB-UHFFFAOYSA-N
- XLogP
- 4.3
- Polar surface area
- 38.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Research
621 papers- Cariprazine for Treating Schizophrenia, Mania, Bipolar Depression, and Unipolar Depression: A Review of Its Efficacy.Cureus · 2023
- Cariprazine.2012
- Cariprazine in Psychiatry: A Comprehensive Review of Efficacy, Safety, and Therapeutic Potential.Medical science monitor : international medical journal of experimental and clinical research · 2024
- Cariprazine.2006
- Cariprazine (Vraylar®).1994
via PubMed
Wikidata facts
- Mass
- 426.1953
Show 6 more facts
- chemical formula
- C₂₁H₃₂Cl₂N₄O
- World Health Organisation international non-proprietary name
- cariprazine
- canonical SMILES
- CN(C(=O)NC1CCC(CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C
- isomeric SMILES
- CN(C(=O)N[C@H]1CC[C@@H](CC1)CCN2CCN(CC2)C3=C(C(=CC=C3)Cl)Cl)C
- Commons category
- Cariprazine
- defined daily dose
- 3
Sources (7)
via Wikidata · CC0
~11 min read
Encyclopedic overview
7 sectionsContents
- Medical uses
- Side effects
- Pharmacology
- Pharmacodynamics
- Pharmacokinetics
- Research
- References
Cariprazine, sold under the brand name Vraylar among others, is an atypical antipsychotic developed by Gedeon Richter, which is used in the treatment of schizophrenia and bipolar disorder. It is also prescribed as an add-on treatment for bipolar depression and major depressive disorder. Cariprazine acts primarily as a D3 and D2 receptor partial agonist, with a preference for the D3 receptor. It is a partial agonist at the serotonin 5-HT1A receptor and acts as an antagonist at 5-HT2B and 5-HT2A receptors. It is taken by mouth. The most prevalent side effects include nausea, mild sedation, fatigue, diabetes regardless of weight changes, and dizziness. At higher dosages, there is an increased risk for restlessness, insomnia, and tremors.
thumb|Bottles of 3mg and 4.5mg Vraylar (cariprazine) capsules showing 3mg capsules below
Excerpted from Wikipedia’s “cariprazine” article, available under the CC BY-SA 4.0 licence.